Evidence map›Paper›PMID 40524116›Full record

SynthesisOral and maxillofacial surgery2025

Pain control and adverse effects of parecoxib after wisdom teeth surgery: a quantitative systematic review.

Othoniel Hugo Aragon-Martinez, Eduardo Gómez-Sánchez, Ronell Bologna-Molina, Nelly Molina-Frechero, Sandra López-Verdín, Nicolás Serafín-Higuera, Juan Manuel Guzmán-Flores, Maikel Hermida-Rojas, Mario Alberto Isiordia-Espinoza

Erratum issuedAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Oral and maxillofacial surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Othoniel Hugo Aragon-MartinezDepartamento de Farmacología, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosi, 78290, México.
Eduardo Gómez-SánchezDivisión de Disciplinas Clínicas, División de Disciplinas Básicas para la Salud, Cuerpo Académico UDG-CA-874 Ciencias Morfológicas en el Diagnóstico y Tratamiento de la Enfermedad, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, 44340, México.
Ronell Bologna-MolinaDepartamento de Patología Molecular, Facultad de Odontología, Universidad de la República (UDELAR), Montevideo, 11200, Uruguay.
Nelly Molina-FrecheroDepartamento de Salud, Laboratorio de Cariología y Medicina Oral, Universidad Autónoma Metropolitana- Xochimilco, Ciudad de México, 04960, Mexico.
Sandra López-VerdínDivisión de Disciplinas Clínicas, División de Disciplinas Básicas para la Salud, Cuerpo Académico UDG-CA-874 Ciencias Morfológicas en el Diagnóstico y Tratamiento de la Enfermedad, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, 44340, México.
Nicolás Serafín-HigueraFacultad de Odontología Mexicali, Universidad Autónoma de Baja California, Baja California, Mexicali, 21040, Mexico.
Juan Manuel Guzmán-FloresDivisión de Ciencias Biomédicas, Centro Universitario de los Altos, Universidad de Guadalajara, Tepatitlán de Morelos 47620, Jalisco, México.
Maikel Hermida-RojasFacultad de Odontología Mexicali, Universidad Autónoma de Baja California, Baja California, Mexicali, 21040, Mexico.
Mario Alberto Isiordia-EspinozaDivisión de Ciencias Biomédicas, Centro Universitario de los Altos, Universidad de Guadalajara, Tepatitlán de Morelos 47620, Jalisco, México. mario.isiordia162@yahoo.com.

Funding

PROSNI 2024 by Dr. Mario Alberto Isiordia-Espinoza PROSNI 2024
6 · The paper itself

Abstract

purposeThe objective of this systematic review was to determine the analgesic efficacy and safety profile of parecoxib in oral surgery. MATERIALS AND

methodsA comprehensive search was conducted in Medline, Scopus, and Embase to locate clinical trials comparing parecoxib with placebo in third molar surgery. The potential for bias in each included study was assessed using the Cochrane Risk of Bias Assessment Tool, and data were extracted on the number of patients experiencing onset of analgesia, the number of patients requiring rescue medication, the overall assessment of the study drugs, and the number of subjects with nausea, dizziness, vomiting, and headache. Statistical analysis was performed using Review Management 5.3 software.

resultsThe results show that patients receiving the 10 mg, 20 mg, and 40 mg doses had better analgesic efficacy compared to those receiving placebo after third molar surgery. Adverse event assessments were similar between the two treatment groups.

conclusionParenteral parecoxib induces high-potency postoperative analgesia, which is effective in managing common postoperative complications following third molar extraction. Furthermore, NNT values ​​and ranges are provided for the analgesic efficacy variables evaluated in this systematic review, allowing clinicians to make informed decisions if multiple analgesics are available for consultation.

Indexed as

Cyclooxygenase 2 InhibitorsIsoxazolesMolar, ThirdPostoperative PainTooth ExtractionHumansCyclooxygenase 2 InhibitorsIsoxazolesparecoxibAnalgesic efficacyNauseaParecoxibPlaceboVomiting

Identifiers

PMID40524116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.